MONDAY, May 7, 2018 -- Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat BRAF-positive anaplastic thyroid cancer. Tafinlar (dabrafenib) and Mekinist (trametinib) combined have been...
Original Article: FDA Approves Drug Combo for Aggressive Thyroid Cancer